Moderna Flu Vaccine Hits Goal, Paves Way for Combo Shot

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines.

- Bloomberg

The shot's efficacy was 27% higher than a licensed influenza vaccine in adults 50 years and older, the company said in a statement Monday. The trial enrolled more than 40,000 adults across 11 countries.

The results set the stage for Moderna to offer a single shot that protects against Covid and flu. US regulators recently told the company that it needed to produce flu vaccine efficacy data—and not just data on the immune response—delaying a potential approval for a combination shot until next year.